Clinical Trials Logo

Clinical Trial Summary

To evaluate the pharmacokinetics (PK) of SPR719, the active moiety, generated from the orally (po) administered SPR720 prodrug in a patient population with nontuberculous mycobacteria pulmonary disease (NTM-PD)

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04553406
Study type Interventional
Source Spero Therapeutics
Status Terminated
Phase Phase 2
Start date December 3, 2020
Completion date January 28, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05192057 - Hypertonic Saline Inhalation for Mycobacterium Avium Complex Pulmonary Disease Phase 4
Withdrawn NCT01719042 - Improving Tolerance of Treatment of Pulmonary MAC Infections Phase 2
Completed NCT00600769 - Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM) Phase 4
Recruiting NCT03236987 - CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections Phase 3
Recruiting NCT04287049 - A Study of Standard Drugs for Mycobacterium Avium Complex Phase 2
Recruiting NCT03672630 - Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease Phase 2/Phase 3
Completed NCT04685720 - A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients N/A
Completed NCT00598962 - Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease Phase 4
Recruiting NCT05824988 - Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
Recruiting NCT02968212 - Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Phase 2